SV2002000362A - PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV - Google Patents

PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV

Info

Publication number
SV2002000362A
SV2002000362A SV2001000362A SV2001000362A SV2002000362A SV 2002000362 A SV2002000362 A SV 2002000362A SV 2001000362 A SV2001000362 A SV 2001000362A SV 2001000362 A SV2001000362 A SV 2001000362A SV 2002000362 A SV2002000362 A SV 2002000362A
Authority
SV
El Salvador
Prior art keywords
msb
proteins
modulating activity
diseases
angiogenesis modulating
Prior art date
Application number
SV2001000362A
Other languages
Spanish (es)
Inventor
Jianmin Chen
Dadong Chen
Alya Zolotorev
Christopher J Davies
Wetzel Gayle Delmonte
Nathalie A Bubois-Stringfello
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Priority to SV2001000362A priority Critical patent/SV2002000362A/en
Publication of SV2002000362A publication Critical patent/SV2002000362A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA BTL-012 ES UNA NUEVA PROTEINA HUMANA UTIL PARA REGULAR O MODULAR LA ANGIOGENESIS. LA BTIL-012 O SUS VARIANTES, PUEDEN EMPLEARSE COMO TERAPIA EN ENFERMEDADES COMO EL CANCER, LA CURACION DE HERIDAS, LA RETINOPATIAS DIABETICAS, LA DEGENERACION MACULAR, Y LAS ENFERMEDADES CARDIOVASCULARES Y OTRAS ENFERMEDADES O CONDICIONES CLINICAS EN LAS CUALES LA ANGIOGENESIS ES RELEVANTE A LA CAUSA O EL TRATAMIENTO DE LA ENFERMEDAD.THE BTL-012 IS A NEW HUMAN PROTEIN USEFUL TO REGULATE OR MODULATE ANGIOGENESIS. THE BTIL-012 OR ITS VARIANTS, MAY BE USED AS A THERAPY IN DISEASES AS CANCER, WOUND HEALING, DIABETIC RETINOPATHICS, MACULAR DEGENERATION, AND OTHER CARDIOVASCULAR DISEASES AND OTHER DISEASES TO LA ANGELES CAUSE OR TREATMENT OF THE DISEASE.

SV2001000362A 2001-03-30 2001-03-30 PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV SV2002000362A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SV2001000362A SV2002000362A (en) 2001-03-30 2001-03-30 PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SV2001000362A SV2002000362A (en) 2001-03-30 2001-03-30 PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV

Publications (1)

Publication Number Publication Date
SV2002000362A true SV2002000362A (en) 2002-07-03

Family

ID=40098672

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000362A SV2002000362A (en) 2001-03-30 2001-03-30 PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV

Country Status (1)

Country Link
SV (1) SV2002000362A (en)

Similar Documents

Publication Publication Date Title
Caetano et al. Phototherapy improves healing of chronic venous ulcers
EA200601777A1 (en) NEW APPLICATION OF PEPTIDE COMPOUNDS FOR THE TREATMENT OF PATIENTS WITH PATIENTS WITH DIABETIC DIABETIC NEUROPATHY
AR039947A1 (en) PHARMACEUTICAL FORMULATION UNDERSTANDING NICOTINE
DE60138549D1 (en) TOPICAL GEL DELIVERY SYSTEMS FOR THE TREATMENT OF SKIN DISEASES
UY28396A1 (en) VEGF TRUMPS AND THERAPEUTIC USES OF THE SAME
EA200400482A1 (en) KERATINOCYCES SUITABLE FOR APPLICATION AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF THE RAS
DE60312309D1 (en) USE OF BOTULINUM TOXIN TO TREAT HEART AND CIRCULAR DISEASES
CY1107248T1 (en) SUSPENED PROTEINS
ECSP055712A (en) SYNERGIC COMBINATION OF SILK PROTEINS
DE602005016392D1 (en) USE OF LOTEPREDNOLETABONATE FOR THE TREATMENT OF DRY EYES
Choi et al. The effect of narrowband ultraviolet B on the expression of matrix metalloproteinase‐1, transforming growth factor‐β1 and type I collagen in human skin fibroblasts
ATE516037T1 (en) TOPICAL FORMULATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
DE602005009974D1 (en) CALIBRATION OF BIOLOGICAL OR PHARMACEUTICAL SUBSTANCES
DE50111204D1 (en) drug mixtures
BR112021013415A2 (en) Multifunctional fusion proteins and uses thereof
ES2113222T3 (en) USE OF BENZOIC ACID DERIVATIVES TO STIMULATE THE EPIDERMIC RENEWAL PROCESS AND TREAT SKIN.
ES2127613T3 (en) USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDDES OF NEUROGENOUS ORIGIN.
CY1124904T1 (en) TYROTHRICIN FOR USE IN THE TREATMENT OR PREVENTION OF BODY ODORS AND PREPARATIONS THEREOF
SV2002000362A (en) PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
GT200100051A (en) PROTEIN THAT HAS ANGIOGENESIS MODULATING ACTIVITY
ATE526057T1 (en) WOUND HEALING BY ADMINISTRATION OF HUMAN IL-18
DE69822276D1 (en) HERBAL FORMULATION WITH THERAPEUTIC AND COSMETIC USE FOR TREATING GENERAL SKIN DISEASES
SV2002000442A (en) METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV
WO2004060316A3 (en) Irs modulators
ATE185274T1 (en) THERAPEUTIC AGENT AGAINST RISK OF ABORTION

Legal Events

Date Code Title Description
FD Lapse